Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;80(6):1281-8.
doi: 10.1111/bcp.12741. Epub 2015 Oct 26.

Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future

Kate O'Hara  1 , Ian M R Wright  2   3   4 , Jennifer J Schneider  5 , Alison L Jones  1   6   7 , Jennifer H Martin  1
Affiliations
Review

Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future

Kate O'Hara et al. Br J Clin Pharmacol. 2015 Dec.

Abstract

Paediatric patients, particularly preterm neonates, present many pharmacological challenges. Due to the difficulty in conducting clinical trials in these populations dosing information is often extrapolated from adult populations. As the processes of absorption, distribution, metabolism and excretion of drugs change throughout growth and development extrapolation presents risk of over or underestimating the doses required. Information about the development these processes, particularly drug metabolism pathways, is still limited with weight based dose adjustment presenting the best method of estimating pharmacokinetic changes due to growth and development. New innovations in pharmacokinetic research, such as population pharmacokinetic modelling, present unique opportunities to conduct clinical trials in these populations improving the safety and effectiveness of the drugs used. More research is required into this area to ensure the best outcomes for our most vulnerable patients.

Keywords: neonate; paediatric; pharmacokinetics; population pharmacokinetic modelling.

PubMed Disclaimer

References

    1. Hoppu K, Anabwani G, Garcia‐Bournissen F, Gazarian M, Kearns GL, Nakamura H, Peterson RG, Sri Ranganathan S, de Wildt SN. The status of paediatric medicines initiatives around the world—what has happened and what has not? Eur J Clin Pharmacol 2011; 68: 1–10. - PubMed
    1. Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 2006; 61: 545–57. - PMC - PubMed
    1. Allegaert K, van de Velde M, van den Anker J. Neonatal clinical pharmacology. Pediatr Anesth 2014; 24: 30–8. - PMC - PubMed
    1. Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NHG. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 2007; 63: 75–84. - PMC - PubMed
    1. Dunne J, Rodriguez WJ, Murphy MD, Beasley BN, Burckart GJ, Filie JD, Lewis LL, Sachs HC, Sheridan PH, Starke P, Yao LP. Extrapolation of adult data and other data in pediatric drug‐development programs. Pediatrics 2011; 128: e1242–e9. - PubMed